British National Formulary (BNF) 90

Product Description

Description
Practical and evidence-based, BNF is an integral part of the UK’s healthcare infrastructure and relied on by health professionals who prescribe, dispense, and administer medicines globally. Containing guidance on best practice in prescribing, as well as legal and ethical considerations, BNF supports safe and effective decision-making at the point of care.

Extensive content updates in the BNF 90 edition include:

New monographs for:
Agamree® [vamorolone] for treatment of Duchenne muscular dystrophy
Anzupgo® [delgocitinib] for treatment of moderate-to-severe hand eczema
Briumvi® [ublituximab] for treatment of multiple sclerosis
Duvyzat® [givinostat] for treatment of Duchenne muscular dystrophy
Joenja® [leniolisib] for treatment of activated phosphoinositide 3-kinase delta syndrome
Kisunla® [donanemab] for treatment of mild cognitive impairment or mild dementia in Alzheimer’s disease
Lunivia® [eszopiclone] for short-term treatment of insomnia
Vafseo® [vadadustat] for treatment of symptomatic anaemia associated with chronic kidney disease in patients on chronic maintenance dialysis
Winlevi® [clascoterone] for treatment of acne vulgaris
Yorvipath® [palopegteriparatide] for treatment of chronic hypoparathyroidism